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SUMOylationAdipocytes are highly specialized cells that play a central role in lipid homeostasis and the maintenance
of energy balance. Obesity, an excessive accumulation of adipose tissue, is a major risk factor for the
development of Type 2 diabetes mellitus (T2DM), cardiovascular disease, and hypertension. A variety of
studies suggest that obesity and T2DM can be linked to a breakdown in the regulatory mechanisms that
control the expression and transcriptional activity of PPARγ. PPARγ is a nuclear hormone receptor that
functions as a master switch in controlling adipocyte differentiation and development. Also important in
controlling glucose homeostasis and insulin sensitivity, PPARγ is a ligand-dependent transcription factor that
is the functional receptor for the anti-diabetic thiazolidinediones (TZDs). In the last ﬁfteen years, a variety of
covalent modiﬁcations of PPARγ activity have been identiﬁed and studied. These covalent modiﬁcations
include phosphorylation, ubiquitylation, O-GlcNAcylation and SUMOylation. Covalent modiﬁcations of
PPARγ represent key regulatory mechanisms that control both PPARγ protein stability and transcriptional
activity. A variety of PPARγ transgenic models, including mice heterozygous for PPARγ, have demonstrated
the importance of PPARγ expression in glucose homeostasis and insulin resistance. In the following review,
we have highlighted the regulation of PPARγ by covalent modiﬁcations, the interplay between these
interactions and how these post-translational modiﬁcations impact metabolic disease states.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
1.1. Role of PPARγ in disease
Our understanding of adipose tissue biology and the role of
adipocytes in obesity-related diseases such as type 2 diabetes (T2DM)
has beneﬁted greatly from the discovery that the lipid-activated
peroxisome proliferator-activated receptor gamma (PPARγ, NR1C3)
nuclear receptor is essential for adipocyte development [1–3]. Sub-
sequent to its discovery as a critical adipogenic transcription factor,
PPARγ was identiﬁed as the pharmacological target of the insulin-
sensitizing thiazolidinediones (TZD) that have been widely used to
treat insulin resistance associated with T2DM [4,5]. Since that time,
various genetic studies using animal models of tissue-speciﬁc PPARγ
deletions have shown that activation of PPARγ in adipose tissue is
central to the insulin-sensitizing effects of the TZDs. Mice lacking
white adipose tissue [6] are not responsive to TZDs and deletion of
PPARγ in adipose tissue causes insulin resistance in adipose and liver,
but not in skeletal muscle [7]. Inhibiting PPARγ activity in mature
adipocytes leads to insulin resistance associated with decreasedrsity, Pennington Biomedical
1 225 763 2648; fax: +1 225
l rights reserved.expression of key genes required for insulin signaling in adipocytes,
reduced uptake of free fatty acids by adipocytes and increased
lipolysis [8,9]. Gain-of-function experiments show that adipocyte-
speciﬁc constitutive activation of PPARγ in mature adipocytes can
regulate whole body insulin sensitivity [10] without stimulating
adipogenesis. Collectively, these observations indicate that PPARγ
activation is as important to lipid and glucose metabolism in fully
formed adipocytes as it is for adipocyte development.
1.2. Regulation of PPARγ activity by protein–protein interactions and
ligand binding
PPARγ is a ligand-activated transcription factor that is expressed
in adipocytes as PPARγ2 and PPARγ1; the two forms differing by a
thirty amino acid N-terminal extension found in PPARγ2 (refer to
Fig. 1). While PPARγ1 is expressed in multiple tissues [11], PPARγ2
is expressed primarily in adipocytes [12]. PPARγ2 is the more
adipogenic PPARγ isoform in vitro [13] and it is also the isoform
transcriptionally regulated by nutrition [11]. PPARγ has an overall
domain structure typical of nuclear hormone receptors. This includes
an N-terminal activation function-1 (AF-1) domain that functions as
a ligand-independent activation domain and confers speciﬁcity of
target gene activation [14]. PPARγ also contains a DNA binding
domain followed by a hinge domain and a large ligand binding domain
that contains a short region at the C-terminus called the activation
Fig. 1. Schematic of PPARγ2 covalent modiﬁcations.
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activation [12] (refer to Fig. 1). PPARγ transcriptional activity is
regulated at multiple levels. PPARγ forms a heterodimeric complex
with RXRα that is mediated by the PPARγ ligand binding domain.
Interaction with RXRα is required for PPARγ to bind the PPARγ
responsive element of its target gene promoters. Once bound to DNA,
PPARγ activation can be modulated by a large number of coregulators
classiﬁed as corepressors and coactivators whose association with
PPARγ is determined by ligand binding to PPARγ. Corepressor pro-
teins that regulate PPARγ activity include the nuclear receptor
corepressor NCoR-1 and its homolog SMRT (silencing mediator for
retinoid and thyroid receptors) [15,16] and the receptor interacting
protein 140 (RIP 140) [17]. In recent studies of transgenicmice lacking
NCoR in adipocytes, it was shown that deletion of this corepressor
leads to increased adipogenesis, reduced inﬂammation, and enhanced
systemic insulin sensitivity [18]. These observations are reminiscent of
a TZD treatment and support other studies that show transcriptionally
active PPARγ promotes insulin sensitivity. In the absence of ligand,
PPARγ can be bound to target gene promoters while associated with
the nuclear corepressors that recruit chromatin-modifying enzymes
to regulate access to the DNA as has been shown in the glycerol kinase
promoter [19]. Of note, the most active cis-regulatory elements
bound by PPARγ differ between mouse and man [20]. Also, studies
in adipocytes and macrophages have demonstrated that PPARγ DNA
binding is predominantly cell type speciﬁc [21]. Upon ligand binding,
the corepressor proteins are replaced by coactivating proteins that
promote PPARγ transcriptional activity. A major category of the
coactivators is the p160 family of proteins that includes the cAMP
response element binding protein (CBP)/p300 and Steroid Receptor
Coactivators (SRC)-1,-2,-3, which recruit histone modiﬁers to the
chromatin structure (reviewed in Ref. [22]). A second category of
coactivators includes subunits of the mediator complex such as the
PPAR-binding protein (PBP)/thyroid hormone receptor-associated
protein (TRAP) 220/ vitamin D receptor-associated protein (DRIP)
205 [23–25]. These coactivators interact with the general transcrip-
tional machinery to control assembly of the transcription preinitiator
complex [23]. TRAP220/DRIP205, originally cloned as a coactivator of
the vitamin D receptor [24], interacts directly with PPARγ [25]. An
additional coactivator, PRIP (peroxisome proliferators-activated re-
ceptor gamma interacting protein) serves to link TRAP220/DRIP205
bound PPARγ to the CBP/p300 coactivator [26]. These coregulators
orchestrate the selective binding of PPARγ to an enormous array of
gene promoters.
Our understanding of the genes regulated by PPARγ binding has
greatly expanded from the set of genes initially identiﬁed as direct
targets of this nuclear receptor. Earlier studies established that PPARγ
controls the expression of genes that are required for lipid synthesis,
transport, and storage [1,27–29] in adipocytes. Recent studies that
take advantage of chromatin immunoprecipitation and genome-wide
sequencing technology demonstrate the PPARγ/RXRα heterodimer
binds to more than 5000 sites, directly activating the expression of a
substantial number of genes involved in lipid and glucose metabolismduring adipogenesis and in mature adipocytes [30–32]. In a majority
of the binding sites, C/EBPα is also present [30,32], in agreement
with the accumulated evidence that PPARγ and C/EBPα activities
coordinate to form a fully functional insulin sensitive adipocyte. The
overlap between PPARγ and C/EBPα binding sites persists in mature
adipocytes [32].
1.3. Regulation of PPARγ by covalent modiﬁcations
As indicated above, PPARγ can be associated with a large number of
proteins. These important protein–protein interactions are noncovalent,
but these interactions control PPARγ activity and can be signiﬁcantly
regulated by covalent modiﬁcations of PPARγ. PPARγ is known to
be modiﬁed by phosphorylation, SUMOylation, O-GlcNAcylation, and
ubiquitylation (refer to Fig. 1). The multiple covalent modiﬁcations of
PPARγ increase the levels of control of both PPARγ expression and
transcriptional activity that contribute to its ability to modulate adi-
pocyte development and insulin sensitivity.
1.3.1. Phosphorylation of PPARγ
Themostwell described of thesemodiﬁcations is phosphorylation of
PPARγ. Growth factor activation of the mitogen activated protein
kinases (MAPK) results in phosphorylation of PPARγ2 in the N-terminal
AF-1 domain at serine112 (Ser82 in PPARγ1) [33–37], the single MAPK
consensus recognition site in PPARγ. The ﬁrst studies on PPARγ
phosphorylation were prompted by observations of the MAPK-
inducing growth factors including epidermal growth factor (EGF),
ﬁbroblast growth factor (FGF) and platelet-derived growth factor
(PDGF) inhibited adipogenesis. Mutation of serine112 to ala-
nine abolishes both the growth factor stimulated phosphoryla-
tion of PPARγ at serine112 and the inhibitory effect of PDGF and EGF
on PPARγ transcriptional activity [35]. In vitro studies have demon-
strated that the non-phosphorylated Ser112Ala mutant form of
PPARγ is more active than wild-type PPARγ in the presence of ligand
[33,36,37]. The MAPK-mediated phosphorylation of PPARγ at
serine112 in the AF-1 domain functions to inhibit PPARγ activity by
regulating ligand binding in the C-terminal ligand binding domain of
PPARγ [38]. The physiological relevance of PPARγ phosphorylation at
serine112 was demonstrated in mice homozygous for the Ser112Ala
mutation of PPARγ2. Although diet-induced obesity is associated with
insulin resistance, elimination of the phosphorylation site protected the
Ser112Ala mice from diet-induced insulin resistance even though the
mice were obese [39]. Preservation of insulin sensitivity in the obese
Ser112Alamice correlatedwith higher expression of PPARγ target genes
and increased serum levels of adiponectin, an insulin-sensitizing factor
secreted exclusively by adipocytes. An additional PPARγ phosphoryla-
tion site at serine273 in the PPARγ ligand-binding domain that is
regulated by Cdk5 [40,41] may have important implications for the
treatment of T2DM. Cdk5-dependent phosphorylation is known to play
a role in neurobiology and neurodegenerative diseases [42,43], but this
kinase is also expressed in non-neuronal tissue, including the insulin
secreting pancreatic beta cells [44], and adipocytes [40]. Cdk5 activity
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regulated in adipose tissue in conditions of obesity and insulin
resistance [46]. The Cdk5-mediated phosphorylation of PPARγ in
adipose tissue has been linked to obesity [40]. Importantly, treatment
with thiazolidinediones, the insulin sensitizing drugs that act as high
afﬁnity PPARγ ligands, increases PPARγ transcriptional activity and
decreases cdk5-dependent phosphorylation of PPARγ2 at serine273.
However, Cdk5 phosphorylation at serine273 of PPARγ2 does not
regulate PPARγ transcriptional activity in general, but does alter the
expression of metabolically important target genes in adipocytes such
as adiponectin. Moreover, PPARγ ligands that are less potent agonists
than the thiazolidinediones, but have insulin-sensitizing effects, also
inhibit Cdk5-mediated phosphorylation in PPARγ2. Transgenic mice
lacking the corepressor NCoR in adipocytes exhibit improvements in
adipogenesis, reduced inﬂammation, and enhanced systemic insulin
sensitivity and a notable decrease in CDK5-mediated PPARγ ser273
phosphorylation [18]. These studies suggest that NCoR can function as
an adaptor protein to enhance the ability of CDK5 to associate with and
phosphorylate PPARγ. Collectively, these studies suggest that phos-
phorylation of PPARγ2 at serine273 by Cdk5 is a key determinant of
whole body insulin sensitivity and that new classes of anti-diabetic
drugs may emerge that are based on regulating Cdk5-mediated phos-
phorylation of the PPARγ ligand binding domain. One compound that
ﬁts these criteria has recently been described [41].
In addition to modulating PPARγ transcriptional activity, MAPK
signaling also affects PPARγ by regulating the subcellular location
of PPARγ. These data demonstrate an interaction of MEK1 with the
C-terminal AF2 domain of PPARγ, yet this interaction does not directly
alter phosphorylation of PPARγ [47,48]. However, there is evidence
that cytoplasmic–nuclear shuttling of PPARγ may be regulated by
phosphorylation of PPARγ in the AF-1 domain at serines 46 and 51 of
PPARγ2 (Ser 16 and Ser 21 of PPARγ1) [49]. In this instance, phos-
phorylation of PPARγ is mediated by casein kinase II (CK-II) and
leads to cytoplasmic localization of PPARγ and decreased PPARγ tran-
scriptional activity. These studies were largely performed in HEK 293
cells and in adipocytes the overall majority of PPARγ is found in the
nucleus. Hence, the physiological relevance of these observations is
still unclear.
1.3.2. SUMOylation of PPARγ
PPARγ is reversibly modiﬁed by SUMO-1 (small ubiquitin-related
modiﬁer) at lysine107 (lysine77 in PPARγ1) and lysine395 (lysine365 in
PPARγ1) [50–53]. First identiﬁed in 1995 [54] as a suppressor of a
centromere-associated protein, SUMO-1 is an approximately 10 kD
protein that regulates protein activity, stability, or cellular location.
Although found in the cytoplasm and nucleus, SUMO-1 is best de-
scribed as regulating a wide range of nuclear functions, including
replication, transcription, DNA repair, and cytoplasmic–nuclear pro-
tein transport [55]. SUMOylation of PPARγ in the N-terminal AF-1
domain (lysine107) strongly represses PPARγ transcriptional activity,
suggesting that SUMO-1 modiﬁcation of PPARγ at lysine107 accounts
for the repressive effect of amino acids 100–138 [56]. The potential
for “crosstalk” between SUMO-1 modiﬁcation at lysine107 and phos-
phorylation at serine112 within this region is supported by at least one
study showing that SUMOylation of PPARγ is impaired in the phos-
phorylation deﬁcient form of PPARγ2 (Ser112Ala) [52], consistent
with the repressive effect of serine112 phosphorylation.
SUMOylation-mediated repression of PPARγ transcriptional activ-
ity occurs even though only a small percentage of PPARγ protein
is modiﬁed by SUMO-1 at steady-state. This disproportionate effect
of SUMOylation on PPARγ activity is consistent with the effect of
SUMOylation on other transcription factors andmay be due to SUMO-
dependent recruitment of “downstream” cofactors that regulate
PPARγ activity. SUMOylation of PPARγ in the AF-1 domain occurs
within a sequence speciﬁc context found in many nuclear recep-
tors that is termed a “synergy control” motif [57,58]. At promoterscontaining multiple response elements, complex protein–protein
interactions with transcription factors give rise to synergistic in-
teractions that control gene expression patterns [59,60]. The repres-
sive activity of the synergy control motif is determined by SUMO-1
(or SUMO-2) modiﬁcation of a lysine within the synergy control
region and the SUMO-1 modiﬁcation provides a surface for inter-
actions with transcriptional repressors such as p300 [61] and the
histone deacetylases [62]. Evidence of the effect of SUMOylation on
the PPARγ AF-1 domain synergy control motif awaits additional
experiments to examine the interactions of PPARγ when modiﬁed
at lysine107 by SUMO-1. However, ligand-dependent SUMOylation
of PPARγ1 at lysine365 (lysine395 in PPARγ2) has been shown to
promote the interaction of PPARγ with nuclear receptor corepressor
(NCoR)-histone deacetylase-3 (HDAC3) complexes in macrophages
[53]. This SUMO-1 dependent interaction prevents removal of the
NCoR-HDAC3 complexes by proteasomal degradation and maintains
repression of PPARγ activity. The physiological relevance of PPARγ
SUMOylation has been observed in FGF21 null mice that have
alterations in PPARγ signaling. Mice lacking FGF21 are lipodystropic
and have less body fat and decreased expression of PPARγ target
genes [63]. These transgenic mice also have increased PPARγ
SUMOylation and FGF21 is capable of inhibiting PPAR SUMOylation
at lysine107. Collectively, these observations suggest that hormones
including FGF21 modulate PPARγ transcriptional activity by regulat-
ing SUMOylation at lysine107 and contribute to whole body insulin
sensitivity. To date, no studies have examined the SUMOylation of the
PPARγ2 ligand-binding domain in adipocytes. Hopefully, future
studies will determine if this modiﬁcation occurs in adipocytes and
if there is any “cross-talk” between SUMO-1 modiﬁcation at lysine395
and Cdk5-dependent phosphorylation at serine273.
1.3.3. Ubiquitylation of PPARγ
SUMO-1 is structurally related to ubiquitin, an 8.5 kD polypeptide
that regulates myriad cellular functions ranging from receptor-
mediated endocytosis to regulation of transcription when covalently
attached to targeted proteins [64]. Proteins modiﬁed by multiple
ubiquitin polypeptides can be targeted to a number of possible fates,
including proteasomal degradation, the best described endpoint
for a polyubiquitylated protein. Covalent modiﬁcation of proteins
by ubiquitin occurs via a highly regulated cascade of enzymes that
catalyze the activation of ubiquitin followed by the transfer of ubiq-
uitin to the targeted protein. The process of activating and trans-
ferring ubiquitin to a substrate is repeated multiple times to form the
polyubiquitin chains that are recognized by the proteasome.
PPARγ proteins have a short half-life in adipocytes [65] and the
turnover rate of PPARγ proteins is regulated by the ubiquitin–
proteasome system under ligand-independent and ligand-dependent
conditions [66,67]. Ligand binding increases ubiquitin modiﬁcation of
PPARγ and proteasomal degradation of PPARγ and in vitro assays
indicate that PPARγ is modiﬁed by ubiquitin in the ligand binding
domain, although the exact site of ubiquitylation has not been
identiﬁed [66,68]. Although ubiquitylation occurs in the absence of
the AF2 domain, the AF2 domain is required for maximal ubiquitin
modiﬁcation of the PPARγ ligand binding domain [68]. This suggests
ubiquitylation of PPARγ may precede coactivator binding of the AF-2
domain and that ubiquitin modiﬁcation of PPARγ functions as an
integral part of PPARγ transcriptional activation. The link between
ubiquitin modiﬁcation of PPARγ and activation of PPARγ is further
supported by the observations that inhibiting proteasome activity
increases PPARγ activity and ubiquitylation in general is required for
PPARγ activity in adipocytes [50,68].
The simplest interpretation of the studies on PPARγ ubiquitylation
is that ubiquitin modiﬁcation of PPARγ regulates PPARγ activity by
controlling the abundance of PPARγ proteins. Regulation of PPARγ
protein steady state levels by promoting ubiquitin modiﬁcation of
PPARγmay represent an important aspect of the action of the insulin
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of insulin resistance show decreased PPARγ gene expression is as
effective as thiazolidinedione activation of PPARγ in improving in-
sulin sensitivity [69–71]. The decreased PPARγ gene expression is
associated with lower steady state levels of PPARγ protein in adipose
tissue [72], lending substantial support to the possibility that modi-
ﬁcation of PPARγ by the ubiquitin–proteasome in adipocytes is an
important regulation of systemic insulin sensitivity that can be
exploited in the treatment of type 2 diabetes.
1.3.4. O-GlcNAcylation of PPARγ
A type of glycosylation that occurs on both cytosol and the nuclear
proteins is the β-O-linked N-acetylglucosamine (O-GlcNAc) post-
translational modiﬁcation. Recent mutational analysis and mass spec-
trometry studies have revealed that the threonine54 in the AF-1 domain
of PPARγ1 (threonine84 in PPARγ2) is a major O-GlcNAc site [73].
The transcriptional activity of wild type PPARγ was inhibited in the
presence of an inhibitor of this modiﬁcation, whereas the threonine
mutant (Thr54Ala) was unresponsive to inhibitor treatment. Although
these studieswere conducted in vitro in cultured 3T3-L1 adipocytes, the
results clearly show that O-GlcNAcylation of PPARγ functions to reduce
PPARγ transcriptional activity.
1.3.5. Potential interplay of PPARγ post-translational modiﬁcations
The phosphorylation and SUMOylation sites in the AF-1 domain of
PPARγ are contained within a highly conserved motif (ψKxExxSP,
where ψ is a hydrophobic residue; in PPARγ the sequence is IK`107
VEPAS112P) that is considered to be a phosphorylation-dependent
SUMOylation motif. Many of the proteins containing this motif are
transcription factors, including the nuclear receptors [74]. In PPARγ,
phosphorylation and SUMOylation in the AF-1 domain function to
repress transcriptional activity. Although phosphorylation within the
“phospho-SUMO switch” in other nuclear receptors acts to block
SUMOylation of the AF-1 domain [75], the evidence that SUMOylation
is impaired in the phosphorylation-deﬁcient form of PPARγ [52]
supports the possibility that phosphorylation of serine112 regulates
SUMOylation of lysine 107 to repress PPARγ activity. In addition,
phosphorylation of serine112 may affect ubiquitylation of PPARγ since
inhibition of MAPK signaling alters the stability of PPARγ and the
level of PPARγ ubiquitylation [66,67]. This may also be the caseFig. 2. Covalent modiﬁcations of PPARγ are asfor SUMOylation. While SUMOylation of lysine107 can occur in
the absence of ubiquitylation, inhibiting SUMO-1 modiﬁcation of
lysine107 increases proteasomal degradation of PPARγ [50], suggest-
ing SUMOylation regulates ubiquitin modiﬁcation of the PPARγ
ligand-binding domain. Stabilization of PPARγ protein via SUMO-1
modiﬁcation is consistent with studies that indicate SUMOylation and
ubiquitylation have opposing functions, but the interplay between
SUMOylation and ubiquitylation in PPARγmay be more complex and
involve cooperative as well as antagonistic functions [76].
Phosphorylation, SUMOylation, and ubiquitylation work in con-
cert with acetylation in many transcription factors, including several
of the nuclear receptors [77]. PPARγ contains twenty potential acety-
lation sites [78], although no sites in PPARγ have been deﬁni-
tively identiﬁed as modiﬁed by acetylation. However, the possibility
of acetylation accompanying phosphorylation, SUMOylation, and
ubiquitylation in regulating PPARγ activity is intriguing given that
four of the potential sites for acetylation overlap or are in close
proximity to SUMOylation and phosphorylation sites in the AF-1 (at
lysines 107 and 119 of PPARγ2) and ligand binding domain (at lysine
268, 272 and 382). Although speculative, it seems highly likely that
acetylation will participate with other covalent modiﬁcations in
regulating the transcriptional activity of PPARγ.
1.4. The role of PPARγ post-translational modiﬁcations in
metabolic disease
It appears that all of the PPARγ covalent modiﬁcations identiﬁed
to date including phosphorylation, SUMOylation, O-GlcNAcylation
and ubiquitylation largely function to decrease PPARγ transcrip-
tional activity and/or expression levels (see Fig. 2). For over a decade,
we have known that PPARγ has been implicated in the regulation
of systemic insulin sensitivity. This was ﬁrst demonstrated when
PPARγwas shown to be the functional receptor for the synthetic anti-
diabetic thiazolidinediones (5). Moreover, direct evidence from
genetic studies in humans has revealed that mutations in the
ligand-binding domain of PPARγ are associated with severe insulin
resistance and T2DM [79]. To date, none of the naturally occurring
genetic mutations in humans has been shown to occur at the exact
residues in PPARγ where covalent modiﬁcations are known to occur.
Nonetheless, these post-translational modiﬁcations have importantsociated with transcriptional repression.
Table 1
Covalent Modiﬁcations of PPARγ2.
Modiﬁcation
of PPARγ2
Site Function
Phosphorylation Serine 112 General decrease in transcriptional
activity
Serine 273 Decrease in activation of speciﬁc
target genes
SUMOylation Lysine 107 Inhibits transcriptional activity
Lysine 395 Prevents NCoR removal to maintain
repression of activity
Ubiquitylation Ligand binding
domain
Targets PPARγ for degradation to
reduce protein expression
O-GlcNAcylation Threonine 84 Inhibits ligand-independent transcriptional activity
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documented missense mutation in the PPARγ2 genes results in the
conversion of proline to glutamine at position 115 and some studies
indicate this polymorphism is associated with obesity [80,81]. Ectopic
expression of this mutant PPARγ results in decreased serine phos-
phorylation and increased PPARγ transcriptional activity [80]. Col-
lectively, these studies revealed that the Pro115Gln mutation in
PPAR2 enhanced the differentiation of adipocytes and this phenotype
was likely a result of decreased serine phosphorylation.
As reviewed above and summarized in Table 1, there are a large
number of studies demonstrating how covalent modiﬁcation of
PPARγ plays a role in modulating its activity and expression levels.
In the last year, two new PPARγ covalent modiﬁcations have been
discovered including O-GlcNAcylation and CDK5 mediated serine
phosphorylation. Also, FGF21 has recently been identiﬁed as a potent
modulator of PPARγ SUMOylation [63]. It will be interesting to learn
whether other insulin sensitizers act by modulating PPARγ covalent
modiﬁcations. Transgenic models of PPARγ modulation have shown
that the activity and expression of PPARγ play a role in both adipocyte
development and insulin sensitivity. Yet, few studies on covalent
modiﬁcation of PPARγ have been performed in the whole animal
setting. To date, the best evidence to support that covalent mod-
iﬁcations of PPARγ may contribute to metabolic disease states comes
from the Lazar laboratory. In these studies, mice containing a PPARγ2
gene that cannot be phosphorylated on serine112 developed obesity
following high fat feeding but were partially protected from diet
induced insulin resistance [34]. Hopefully, future studies will reveal
equally important roles for other post translational modiﬁcation of
PPARγ under physiological and/or pathological conditions. The ability
to modulate PPARγ activity and improve insulin sensitivity by spe-
ciﬁcally inhibiting a covalent modiﬁcation of PPARγ may represent a
viable therapeutic option in the treatment of insulin resistance and
T2DM.
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